Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Dishman Carbogen Amcis Limited (DCAL)
Small CapPharma stocks · Small cap · NSE
Dishman Carbogen Amcis Limited operates in CRAMS/CDMO, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result14 Aug, 07:53 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
53Neutralfull bear SMA stack · SMA20 -9.6% / mo · RSI oversold · MACD − · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 22
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
DCALD candles · FIT view-18.7%Latest close ₹142.10 on 2026-10-21
Bar
-2.5%
RSI
29
MACD hist
-0.31
52W pos
8%
2026-10-21O ₹145.80H ₹146.39L ₹140.41C ₹142.10Vol 1.8L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
DCALNifty PharmaNifty 500
- DCAL
- -25.3%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -18.8 pp
Chart stats
21 Oct 2026- From 52W high
- -53.1%
- 52W range position
- 8%
- ATR (14)
- 4.0%
- Volume vs 20D
- 1.24x
- Avg traded value
- ₹2.3 Cr
- 20D price channel
- ₹140.4 - ₹174.5
₹303
₹128.5 - ₹303
₹5.6
Latest completed session
20-session average
31.6% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
Legacy · WATCHLIST41
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -4.2% · PAT -352.2% YoY
Technical
Neutral53
Price trend and sector-relative-strength timing.
Valuation
Legacy model-206.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence63
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100Rev -4% YoY · PAT -352% YoY · margin compression
Filed 14 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹678 Cr | -4.2% | -20.3% |
| EBITDA | ₹60 Cr | -57.4% | -63.2% |
| Operating margin | 9.0% | -1100 bps | -1000 bps |
| PAT | ₹-58 Cr | -352.2% | -363.6% |
| PAT margin | -8.6% | -1180 bps | -1114 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 131.00
- P/B
- 0.36
- EV/EBITDA
- 6.54
- Market Cap
- 2369.00Cr
Profitability
- ROE
- 1.58%
- ROCE
- 3.14%
- ROA
- 0.13%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 9.00%
- EPS 5Y
- 21.00%
- Revenue 3Y
- 7.00%
- EPS 3Y
- 52.50%
Balance Sheet
- Debt/Equity
- 0.46
- Interest Coverage
- 2.87×
- Altman Z
- 1.63
- Book Value
- 426.00
Cash Flow
- FCF Yield
- 10.38%
- FCF Positive Y
- 7/5
- OCF
- 491.00 Cr
- EPS TTM
- 1.03
Shareholding
- Promoter Hold
- 59.32%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 13%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 678-20.3% vs prev
Net Profit
₹ CrLatest: -58.0-363.6% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 29.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~10.7% over last month) — short-term momentum negative.
- RSI(14) at 29 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 53% off 52W high · 11% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
10
RS percentile
Stage 4 Downtrend
1M return
-16.7%
3M return
-25.3%
6M return
-18.6%
1Y return
-51.5%
RS 1D
0
RS 20D
-16
Sector rank
#1
Industry rank
#9
Stage evidence
- Price is 18.9% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.0%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 54.75-1.63%
RS vs Nifty 50055
Valuation & peers
U-Score 41 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 41 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Distress Watch
Fundamental score breakdown
U band · WATCHLISTValuation5/30
Growth16/25
Quality0/20
Balance Sheet4/15
Cash Flow10/10
Piotroski
7/9 (+5)
Penalties
1
Raw sum
41
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
41/100 · legacy band WATCHLIST
Positive drivers
- FCF yield is supportive at 10.4%.
- Piotroski is strong at 7/9.
- Cash flow contributes 10/10 to the score.
Main drags
- Altman Z is 1.6, in distress territory.
- Fair-value margin of safety is negative at -206.6%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
131.0
PB
0.4
EV/EBITDA
6.5
ROE
1.6%
ROCE
3.1%
FCF Yield
10.4%
Debt/Equity
0.5
MoS
-206.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
41
Previous: 41
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-206.6%
Previous: -214.6%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
41
41
41
41
41
41
41
41
41
41
41
41
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹99.36
-43.0% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹46.35
-206.6% MoS
PEG
3.90
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
HIKAL
Small
Hikal Limited
Pharmaceuticals
match 166
30
62.4
2.2%
-3367%
OVERVALUED
SYNGENE
Small
Syngene International Limited
Pharmaceuticals
match 149
29
52.7
7.8%
-1179%
OVERVALUED
COHANCE
Small
Cohance Lifesciences Limited
Pharmaceuticals
match 149
23
165.0
4.9%
-4672%
OVERVALUED
AKUMS
Large
Akums Drugs and Pharmaceuticals Limited
Pharmaceuticals
match 144
42
37.8
8.4%
+15%
WATCHLIST
DIVISLAB
Large
Divi's Laboratories Limited
Pharmaceuticals
match 144
43
81.5
16.5%
-485%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Dishman Carbogen Amcis Limited operates in CRAMS/CDMO, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
63Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 38th percentile of the scored universe and 27th percentile within Pharma. Main check: results consistency is weak at 27/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
133 docs text-extracted · 53 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
38th percentile
overall median 67 · Pharma: 27th pctile, median 70 · Small: 43rd pctile, median 66
Evidence depth
Financial-only
133 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
89
strong · profit to cash conversion
Balance sheet
55
watch · leverage and solvency
Discipline
40
weak · capital discipline
Results
27
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 59.3%.
- ▸Promoter pledge is zero.
- ▸FCF yield is 9%.
- ▸7 years of positive FCF.
Trust risks
- ▸Altman Z is 1.67.
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 3.2%.
- ▸ROE is low at 1.6%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Dishman Carbogen Amcis Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Allotment 17 Aug - Allotted 7,500 NCDs of Rs 1 lakh each, raising Rs 75 crore on 17 August 2026.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Aug - Conference call on 17 Aug 2026 for Q1FY27 financial results discussion.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 12 Aug - Dishman Carbogen Amcis revised its Q1FY27 conference call link; results on 14 Aug 2026, call on 17 Aug 2026.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Jul - Pls. find enclosed herewith Newspaper Advertisement published on 17th July, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 29 Jun - Subsidiary commissioned 1,200 kWp photovoltaic system at Neuland site in Switzerland.
Source: Bse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Bse
Investor presentationMay 2026
May 2026 · PPT
Source: Bse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Bse
Investor presentationMay 2026
May 2026 · PPT
Source: Bse
Announcement
Outcome Of Board Meeting Held On 19Th May, 2026. 2d
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.